NYSE · Healthcare
WEST PHARMACEUTICAL SERVICES INC (WST)
As-reported financials and recent SEC filings for WEST PHARMACEUTICAL SERVICES INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.07B
Net income
$493.7M
Net margin
16.1%
Diluted EPS
$6.79
ROE
15.5%
P/E (TTM)
47.0×
Market cap
$24.79B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Gross profit | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| Diluted EPS | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-01
View on EDGAR →8-K/A2026-05-20
View on EDGAR →42026-05-14
View on EDGAR →SD2026-05-13
View on EDGAR →8-K2026-05-11
View on EDGAR →1442026-05-07
View on EDGAR →42026-05-06
View on EDGAR →42026-05-06
View on EDGAR →Go deeper on WST
Search WEST PHARMACEUTICAL SERVICES INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.